A Dominant Role for p53-Dependent Cellular Senescence in Radiosensitization of Human Prostate Cancer Cells

Because p53 inactivation may limit the effectiveness of radiation therapy for localized prostate cancer, it is important to understand how this gene regulates clonogenic survival after an exposure to ionizing radiation. Here, we show that premature cellular senescence is the principal mode of cell death accounting for the radiosensitivity of human prostate cancer cell lines retaining p53 function. Alternative stress response pathways controlled by this tumor suppressor, including cell cycle arrest, DNA damage repair, mitotic catastrophe and apoptosis, contributed significantly less to radiation-induced clonogenic death. Using a dominant negative C-terminal fragment of p53, we present the first evidence that a complete loss of endogenous p53 function is sufficient to limit the irradiation-induced senescence and clonogenic death of prostate cancer cells. Conversely, inheritance of wild-type p53 by prostate cancer cells lacking a functional allele of this gene (i.e., DU145) significantly increases clonogenic death through p53-dependent cellular senescence and apoptotic pathways. Our data provide evidence that mutations of even one p53 allele may be sufficient to alter their clonogenic fate. In addition, they support the idea that the p53 pathway can be used as a specific target for enhancing the radiosensitivity of prostate cancer cells. Activation of p53 by the drug nutlin-3 is shown to be an effective radiosensitizer of prostate cancer cells retaining functional alleles of p53 and this effect was entirely attributable to an increased induction of p53-dependent cellular senescence.

[1]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  R. Macklis,et al.  E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma , 2007, Oncogene.

[3]  K. W. Kim,et al.  Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. , 2006, Cancer research.

[4]  E. Venkatraman,et al.  Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[5]  B. Strauss,et al.  The DU145 human prostate carcinoma cell line harbors a temperature‐sensitive allele of p53 , 2006, The Prostate.

[6]  G. Fronza,et al.  Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function , 2006, Journal of cellular biochemistry.

[7]  N. Gueven,et al.  The complexity of p53 stabilization and activation , 2006, Cell Death and Differentiation.

[8]  F. Sarkar,et al.  Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest , 2006, BMC Cancer.

[9]  D. Hallahan,et al.  Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2 , 2006, Molecular Cancer Therapeutics.

[10]  J. Nakamura,et al.  Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. , 2005, International journal of radiation oncology, biology, physics.

[11]  R. Bristow,et al.  Optimal treatment of intermediate‐risk prostate carcinoma with radiotherapy , 2005, Cancer.

[12]  Shivendra V. Singh,et al.  Checkpoint Kinase 1 Regulates Diallyl Trisulfide-induced Mitotic Arrest in Human Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.

[13]  Yves Pommier,et al.  Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage. , 2005, Biochemical and biophysical research communications.

[14]  Vijay S Pande,et al.  Dimerization of the p53 oligomerization domain: identification of a folding nucleus by molecular dynamics simulations. , 2005, Journal of molecular biology.

[15]  N. Morita,et al.  Centrosome Hyperamplification and Chromosomal Damage after Exposure to Radiation , 2005, Oncology.

[16]  T. DeWeese,et al.  Evasion of Early Cellular Response Mechanisms following Low Level Radiation-induced DNA Damage* , 2004, Journal of Biological Chemistry.

[17]  P. Olive,et al.  Radiation Sensitivity, H2AX Phosphorylation, and Kinetics of Repair of DNA Strand Breaks in Irradiated Cervical Cancer Cell Lines , 2004, Cancer Research.

[18]  J. Shay,et al.  Hallmarks of senescence in carcinogenesis and cancer therapy , 2004, Oncogene.

[19]  R. Poon,et al.  How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer? , 2004, Molecular and Cellular Biology.

[20]  M. Cooperberg,et al.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.

[21]  J. Dahm-Daphi,et al.  Reply: Tumour and normal cells differ in the induction and repair of DNA double-strand breaks , 2004, British Journal of Cancer.

[22]  J. Dahm-Daphi,et al.  Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells , 2004, International journal of radiation biology.

[23]  J. Earle,et al.  Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. , 2003, Cancer research.

[24]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[25]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Akudugu,et al.  Studies on the influence of DNA repair on radiosensitivity in prostate cell lines , 2003, Urological Research.

[27]  R. Bristow,et al.  Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill , 2003, Prostate Cancer and Prostatic Diseases.

[28]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[29]  T. Jacks,et al.  Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  I. Roninson,et al.  Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Sugimura,et al.  Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. , 2001, International journal of radiation oncology, biology, physics.

[32]  P. Tofilon,et al.  Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. , 2000, International journal of radiation oncology, biology, physics.

[33]  M. Müller,et al.  PTEN/MMAC1 mutations in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[34]  M. Fenech The in vitro micronucleus technique. , 2000, Mutation research.

[35]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[36]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[37]  T. DeWeese,et al.  Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. , 1998, The Journal of urology.

[38]  M. Grütter,et al.  In vitro structure-function analysis of the beta-strand 326-333 of human p53. , 1997, Journal of molecular biology.

[39]  G. Hanks,et al.  Radiation inactivation of human prostate cancer cells: the role of apoptosis. , 1996, Radiation research.

[40]  Jay W. Ponder,et al.  Accurate modeling of the intramolecular electrostatic energy of proteins , 1995, J. Comput. Chem..

[41]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[42]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[43]  S. Deb,et al.  Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. , 1994, Oncogene.

[44]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[45]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[46]  J. Milner,et al.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.

[47]  C. Belloir,et al.  Desmoid tumors in adults: the role of radiotherapy in their management. , 1988, American journal of surgery.

[48]  J. McCubrey,et al.  Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes. , 2003, Methods in molecular biology.

[49]  M. Macera,et al.  Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNAse cleavage assay in prostate cancer. , 1999, Cancer genetics and cytogenetics.

[50]  E. Rosen,et al.  The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. , 1999, Cancer investigation.

[51]  J. Leith,et al.  Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: comparative cellular radiosensitivity and hypoxic percentages. , 1994, Acta neurochirurgica. Supplement.

[52]  P. Olive,et al.  Lack of a correlation between radiosensitivity and DNA double-strand break induction or rejoining in six human tumor cell lines. , 1994, Cancer research.

[53]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.

[54]  M. Menon,et al.  Radiosensitivity of human prostate cancer and malignant melanoma cell lines. , 1989, Radiotherapy and Oncology.